| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neutrophils | 87 | 2022 | 1176 | 10.230 |
Why?
|
| Blood Coagulation Disorders | 42 | 2023 | 197 | 9.880 |
Why?
|
| Wounds and Injuries | 72 | 2023 | 749 | 9.150 |
Why?
|
| Fibrinolysis | 32 | 2023 | 158 | 9.050 |
Why?
|
| Shock, Hemorrhagic | 46 | 2023 | 199 | 7.410 |
Why?
|
| Acute Lung Injury | 31 | 2018 | 299 | 6.070 |
Why?
|
| Thrombelastography | 50 | 2023 | 180 | 5.430 |
Why?
|
| Plasma | 30 | 2022 | 211 | 5.400 |
Why?
|
| Transfusion Reaction | 29 | 2021 | 65 | 5.330 |
Why?
|
| Tissue Plasminogen Activator | 19 | 2023 | 225 | 5.140 |
Why?
|
| Blood Preservation | 32 | 2021 | 263 | 4.790 |
Why?
|
| Erythrocyte Transfusion | 28 | 2022 | 189 | 4.030 |
Why?
|
| Blood Component Transfusion | 15 | 2020 | 78 | 3.980 |
Why?
|
| Resuscitation | 31 | 2023 | 252 | 3.910 |
Why?
|
| Blood Platelets | 25 | 2022 | 351 | 3.800 |
Why?
|
| Erythrocytes | 22 | 2022 | 591 | 3.610 |
Why?
|
| Neutrophil Activation | 17 | 2018 | 94 | 3.090 |
Why?
|
| Blood Transfusion | 27 | 2022 | 293 | 2.790 |
Why?
|
| Multiple Organ Failure | 30 | 2023 | 146 | 2.740 |
Why?
|
| Blood Coagulation | 17 | 2023 | 218 | 2.690 |
Why?
|
| Thrombin | 10 | 2023 | 139 | 2.520 |
Why?
|
| Hemorrhage | 16 | 2023 | 620 | 2.370 |
Why?
|
| Platelet Activating Factor | 21 | 2019 | 90 | 2.260 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 8 | 2023 | 83 | 2.240 |
Why?
|
| Saline Solution, Hypertonic | 14 | 2019 | 53 | 2.080 |
Why?
|
| Fibrinogen | 11 | 2023 | 154 | 2.010 |
Why?
|
| Lysophosphatidylcholines | 10 | 2016 | 30 | 2.000 |
Why?
|
| Thrombophilia | 6 | 2023 | 67 | 1.740 |
Why?
|
| Proteomics | 21 | 2023 | 836 | 1.680 |
Why?
|
| NADPH Oxidases | 15 | 2016 | 120 | 1.630 |
Why?
|
| Lung | 24 | 2023 | 3561 | 1.620 |
Why?
|
| Lipids | 12 | 2017 | 580 | 1.610 |
Why?
|
| Humans | 243 | 2023 | 114698 | 1.610 |
Why?
|
| Rats | 35 | 2023 | 4958 | 1.510 |
Why?
|
| Fibrinolysin | 4 | 2023 | 15 | 1.510 |
Why?
|
| Antifibrinolytic Agents | 7 | 2023 | 50 | 1.480 |
Why?
|
| Receptors, G-Protein-Coupled | 8 | 2012 | 194 | 1.470 |
Why?
|
| Lymph | 9 | 2016 | 40 | 1.450 |
Why?
|
| Fibrinolytic Agents | 4 | 2022 | 234 | 1.410 |
Why?
|
| Superoxides | 24 | 2011 | 214 | 1.410 |
Why?
|
| Thrombosis | 6 | 2023 | 298 | 1.350 |
Why?
|
| Endothelial Cells | 9 | 2023 | 687 | 1.350 |
Why?
|
| Antibodies | 7 | 2016 | 371 | 1.330 |
Why?
|
| Blood Proteins | 8 | 2018 | 231 | 1.320 |
Why?
|
| Metabolome | 7 | 2022 | 282 | 1.310 |
Why?
|
| Rats, Sprague-Dawley | 34 | 2019 | 2218 | 1.280 |
Why?
|
| Calcium | 18 | 2023 | 1108 | 1.280 |
Why?
|
| Cell Membrane | 8 | 2016 | 680 | 1.280 |
Why?
|
| Male | 130 | 2023 | 55606 | 1.250 |
Why?
|
| Platelet Transfusion | 9 | 2023 | 64 | 1.240 |
Why?
|
| Leukocyte Reduction Procedures | 3 | 2018 | 25 | 1.190 |
Why?
|
| Leukocyte Elastase | 9 | 2017 | 80 | 1.150 |
Why?
|
| Protein Kinase C | 3 | 2017 | 273 | 1.150 |
Why?
|
| Transfusion-Related Acute Lung Injury | 4 | 2019 | 4 | 1.150 |
Why?
|
| Hemoglobins | 7 | 2022 | 315 | 1.130 |
Why?
|
| Injury Severity Score | 25 | 2023 | 499 | 1.110 |
Why?
|
| Endothelium, Vascular | 14 | 2023 | 847 | 1.090 |
Why?
|
| Blood Substitutes | 5 | 2015 | 27 | 1.090 |
Why?
|
| Multiple Trauma | 9 | 2023 | 96 | 1.040 |
Why?
|
| Tranexamic Acid | 5 | 2020 | 39 | 1.040 |
Why?
|
| Platelet Aggregation | 4 | 2022 | 94 | 1.030 |
Why?
|
| Adult | 79 | 2023 | 30553 | 1.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 9 | 2003 | 278 | 1.010 |
Why?
|
| Animals | 75 | 2023 | 31708 | 1.000 |
Why?
|
| Plasminogen | 4 | 2023 | 33 | 0.980 |
Why?
|
| Disease Models, Animal | 27 | 2023 | 3535 | 0.960 |
Why?
|
| ABO Blood-Group System | 3 | 2022 | 32 | 0.920 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 10 | 2013 | 260 | 0.910 |
Why?
|
| Mesentery | 12 | 2015 | 53 | 0.900 |
Why?
|
| beta-Globins | 2 | 2022 | 10 | 0.900 |
Why?
|
| Pancreatic Elastase | 11 | 2016 | 66 | 0.880 |
Why?
|
| Female | 96 | 2023 | 59520 | 0.880 |
Why?
|
| Bradykinin | 1 | 2023 | 42 | 0.860 |
Why?
|
| Lung Injury | 6 | 2016 | 198 | 0.860 |
Why?
|
| Arachidonic Acid | 4 | 2022 | 116 | 0.860 |
Why?
|
| Carboxypeptidase B2 | 1 | 2023 | 4 | 0.850 |
Why?
|
| Uterine Inertia | 1 | 2022 | 1 | 0.840 |
Why?
|
| Intercellular Adhesion Molecule-1 | 7 | 2015 | 154 | 0.840 |
Why?
|
| Respiratory Burst | 12 | 2016 | 28 | 0.830 |
Why?
|
| Cytokines | 11 | 2021 | 1841 | 0.830 |
Why?
|
| Lung Diseases | 8 | 2008 | 701 | 0.830 |
Why?
|
| Postpartum Hemorrhage | 1 | 2022 | 14 | 0.830 |
Why?
|
| Cytotoxicity, Immunologic | 7 | 2006 | 195 | 0.820 |
Why?
|
| Enzyme Activation | 14 | 2017 | 785 | 0.810 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2022 | 151 | 0.780 |
Why?
|
| Sodium Chloride | 4 | 2018 | 136 | 0.740 |
Why?
|
| Oxidoreductases | 3 | 2011 | 92 | 0.740 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2014 | 1140 | 0.740 |
Why?
|
| Brain Injuries, Traumatic | 6 | 2023 | 303 | 0.740 |
Why?
|
| Bronchopulmonary Sequestration | 1 | 2020 | 9 | 0.720 |
Why?
|
| Blood Component Removal | 3 | 2021 | 29 | 0.720 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2020 | 3 | 0.720 |
Why?
|
| Phosphoproteins | 5 | 2009 | 298 | 0.720 |
Why?
|
| Inflammation | 16 | 2023 | 2480 | 0.720 |
Why?
|
| Macrophage-1 Antigen | 8 | 2002 | 33 | 0.700 |
Why?
|
| In Vitro Techniques | 12 | 2020 | 1016 | 0.690 |
Why?
|
| Inflammation Mediators | 3 | 2013 | 477 | 0.680 |
Why?
|
| Receptors, Leukotriene B4 | 2 | 2017 | 8 | 0.680 |
Why?
|
| Clathrin | 3 | 2010 | 27 | 0.680 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 13 | 2008 | 65 | 0.680 |
Why?
|
| Middle Aged | 51 | 2023 | 26738 | 0.680 |
Why?
|
| Hemolysis | 3 | 2022 | 146 | 0.660 |
Why?
|
| Interleukin-8 | 8 | 2013 | 237 | 0.660 |
Why?
|
| Platelet Membrane Glycoproteins | 6 | 2009 | 39 | 0.650 |
Why?
|
| Blood Transfusion, Autologous | 3 | 2011 | 19 | 0.650 |
Why?
|
| Succinic Acid | 5 | 2020 | 44 | 0.640 |
Why?
|
| Leukapheresis | 4 | 2011 | 25 | 0.640 |
Why?
|
| Point-of-Care Systems | 5 | 2021 | 136 | 0.640 |
Why?
|
| MAP Kinase Signaling System | 4 | 2008 | 276 | 0.640 |
Why?
|
| Proto-Oncogene Proteins c-hck | 2 | 2016 | 3 | 0.640 |
Why?
|
| Wounds, Nonpenetrating | 6 | 2023 | 256 | 0.630 |
Why?
|
| Healthy Volunteers | 6 | 2020 | 197 | 0.630 |
Why?
|
| Cytoplasmic Granules | 1 | 2018 | 82 | 0.620 |
Why?
|
| Leukotriene B4 | 6 | 2011 | 48 | 0.610 |
Why?
|
| Balloon Occlusion | 3 | 2023 | 26 | 0.610 |
Why?
|
| Filtration | 2 | 2018 | 59 | 0.600 |
Why?
|
| Cytosol | 7 | 2010 | 208 | 0.590 |
Why?
|
| Phospholipases A | 6 | 2002 | 101 | 0.590 |
Why?
|
| Platelet Function Tests | 3 | 2019 | 24 | 0.590 |
Why?
|
| Metabolomics | 8 | 2023 | 521 | 0.580 |
Why?
|
| Prospective Studies | 20 | 2022 | 6220 | 0.570 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 551 | 0.570 |
Why?
|
| Time Factors | 25 | 2019 | 6116 | 0.570 |
Why?
|
| Sex Characteristics | 4 | 2022 | 641 | 0.570 |
Why?
|
| Refrigeration | 1 | 2017 | 11 | 0.570 |
Why?
|
| Isoantibodies | 5 | 2018 | 57 | 0.560 |
Why?
|
| Osmolar Concentration | 4 | 2013 | 173 | 0.560 |
Why?
|
| Pulmonary Edema | 6 | 2019 | 115 | 0.560 |
Why?
|
| Pancreatic Neoplasms | 7 | 2013 | 731 | 0.560 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2018 | 797 | 0.560 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2014 | 28 | 0.550 |
Why?
|
| Blood Donors | 5 | 2014 | 89 | 0.550 |
Why?
|
| Endocytosis | 2 | 2009 | 148 | 0.550 |
Why?
|
| Microvessels | 2 | 2017 | 68 | 0.540 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2016 | 352 | 0.540 |
Why?
|
| Blood Coagulation Tests | 6 | 2023 | 57 | 0.520 |
Why?
|
| Adenosine Diphosphate | 5 | 2022 | 81 | 0.520 |
Why?
|
| Microcirculation | 2 | 2017 | 135 | 0.520 |
Why?
|
| Protein Kinase C-delta | 1 | 2016 | 70 | 0.510 |
Why?
|
| Systemic Inflammatory Response Syndrome | 4 | 2015 | 72 | 0.510 |
Why?
|
| Receptor, PAR-2 | 1 | 2015 | 8 | 0.500 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2015 | 30 | 0.500 |
Why?
|
| Models, Immunological | 2 | 2013 | 92 | 0.500 |
Why?
|
| Lymphatic System | 3 | 2004 | 12 | 0.490 |
Why?
|
| Cells, Cultured | 15 | 2023 | 3886 | 0.490 |
Why?
|
| Trauma Centers | 12 | 2021 | 362 | 0.490 |
Why?
|
| Interleukin-18 | 2 | 2009 | 219 | 0.480 |
Why?
|
| Thrombolytic Therapy | 1 | 2015 | 117 | 0.470 |
Why?
|
| Phosphorylation | 10 | 2016 | 1569 | 0.470 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2014 | 493 | 0.470 |
Why?
|
| Protein Kinases | 3 | 2010 | 307 | 0.470 |
Why?
|
| Mass Spectrometry | 11 | 2018 | 633 | 0.460 |
Why?
|
| Plateletpheresis | 3 | 2018 | 25 | 0.460 |
Why?
|
| Liver | 3 | 2018 | 1637 | 0.450 |
Why?
|
| Hemostasis | 3 | 2023 | 67 | 0.450 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2014 | 10 | 0.450 |
Why?
|
| Hemoglobinopathies | 1 | 2014 | 4 | 0.450 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 444 | 0.450 |
Why?
|
| Abdominal Injuries | 1 | 2015 | 108 | 0.450 |
Why?
|
| HLA-A2 Antigen | 1 | 2013 | 36 | 0.450 |
Why?
|
| Apoptosis | 7 | 2014 | 2363 | 0.440 |
Why?
|
| Cell-Derived Microparticles | 1 | 2014 | 57 | 0.430 |
Why?
|
| CD18 Antigens | 8 | 2008 | 33 | 0.430 |
Why?
|
| Proteome | 3 | 2023 | 339 | 0.430 |
Why?
|
| Anticoagulants | 4 | 2023 | 550 | 0.420 |
Why?
|
| Swine | 12 | 2023 | 700 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 1262 | 0.410 |
Why?
|
| Leukocytes | 4 | 2017 | 276 | 0.410 |
Why?
|
| Wounds, Penetrating | 4 | 2018 | 73 | 0.410 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2017 | 414 | 0.400 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2009 | 351 | 0.400 |
Why?
|
| Blast Injuries | 2 | 2022 | 42 | 0.390 |
Why?
|
| Translocation, Genetic | 2 | 2005 | 95 | 0.390 |
Why?
|
| Lipopolysaccharides | 9 | 2016 | 823 | 0.390 |
Why?
|
| Acute Chest Syndrome | 1 | 2011 | 2 | 0.380 |
Why?
|
| Pneumonia | 2 | 2017 | 568 | 0.380 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2011 | 23 | 0.380 |
Why?
|
| Risk Factors | 17 | 2022 | 8632 | 0.380 |
Why?
|
| Splenomegaly | 1 | 2011 | 17 | 0.380 |
Why?
|
| Hemodilution | 1 | 2011 | 10 | 0.380 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2011 | 40 | 0.370 |
Why?
|
| Hemoglobin SC Disease | 1 | 2011 | 15 | 0.370 |
Why?
|
| Phenotype | 6 | 2019 | 2796 | 0.370 |
Why?
|
| NADH, NADPH Oxidoreductases | 4 | 1996 | 18 | 0.370 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2011 | 30 | 0.370 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2010 | 15 | 0.360 |
Why?
|
| Estradiol | 3 | 2022 | 455 | 0.360 |
Why?
|
| Shock, Traumatic | 2 | 2015 | 17 | 0.360 |
Why?
|
| CD40 Ligand | 2 | 2011 | 39 | 0.360 |
Why?
|
| Arrestins | 2 | 2010 | 14 | 0.360 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 231 | 0.350 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2009 | 172 | 0.350 |
Why?
|
| Endosomes | 2 | 2008 | 124 | 0.340 |
Why?
|
| Abdominal Pain | 1 | 2011 | 135 | 0.340 |
Why?
|
| Adenocarcinoma | 5 | 2012 | 795 | 0.340 |
Why?
|
| Receptors, Cell Surface | 4 | 2003 | 355 | 0.340 |
Why?
|
| Tyrosine | 4 | 2003 | 214 | 0.340 |
Why?
|
| Isoantigens | 2 | 2006 | 17 | 0.340 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2013 | 401 | 0.330 |
Why?
|
| Cardiopulmonary Bypass | 4 | 2008 | 178 | 0.330 |
Why?
|
| Amantadine | 1 | 2009 | 7 | 0.330 |
Why?
|
| Fibrin | 2 | 2022 | 65 | 0.330 |
Why?
|
| Adolescent | 24 | 2019 | 17853 | 0.320 |
Why?
|
| Hemostatic Techniques | 3 | 2018 | 40 | 0.310 |
Why?
|
| Endovascular Procedures | 2 | 2023 | 269 | 0.310 |
Why?
|
| alpha-Globins | 2 | 2022 | 11 | 0.310 |
Why?
|
| Biomarkers | 12 | 2022 | 3408 | 0.310 |
Why?
|
| Cell Adhesion | 6 | 2013 | 432 | 0.310 |
Why?
|
| rab5 GTP-Binding Proteins | 1 | 2008 | 6 | 0.310 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 2023 | 590 | 0.310 |
Why?
|
| Angiogenic Proteins | 1 | 2008 | 18 | 0.310 |
Why?
|
| Isotonic Solutions | 6 | 2016 | 39 | 0.300 |
Why?
|
| Actins | 2 | 2009 | 381 | 0.300 |
Why?
|
| Carcinogens | 1 | 2008 | 103 | 0.290 |
Why?
|
| Protein Transport | 4 | 2016 | 395 | 0.290 |
Why?
|
| Egtazic Acid | 4 | 2002 | 44 | 0.290 |
Why?
|
| Recombinant Proteins | 2 | 2016 | 1230 | 0.280 |
Why?
|
| Splanchnic Circulation | 2 | 2004 | 12 | 0.280 |
Why?
|
| Brain Injuries | 2 | 2022 | 461 | 0.280 |
Why?
|
| Case-Control Studies | 10 | 2019 | 3003 | 0.280 |
Why?
|
| Prognosis | 9 | 2022 | 3329 | 0.280 |
Why?
|
| Liver Transplantation | 3 | 2017 | 707 | 0.280 |
Why?
|
| Trauma Severity Indices | 4 | 2020 | 114 | 0.280 |
Why?
|
| HLA Antigens | 5 | 2018 | 225 | 0.280 |
Why?
|
| Models, Biological | 5 | 2009 | 1621 | 0.270 |
Why?
|
| Azepines | 6 | 2001 | 75 | 0.270 |
Why?
|
| Protein C | 2 | 2023 | 45 | 0.270 |
Why?
|
| Organ Preservation Solutions | 2 | 2018 | 39 | 0.270 |
Why?
|
| Amino Acids | 2 | 2022 | 448 | 0.260 |
Why?
|
| Arachidonate 5-Lipoxygenase | 2 | 2018 | 45 | 0.260 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 329 | 0.260 |
Why?
|
| Aged | 19 | 2019 | 19074 | 0.260 |
Why?
|
| Pilot Projects | 4 | 2022 | 1373 | 0.260 |
Why?
|
| Reperfusion Injury | 3 | 2018 | 255 | 0.260 |
Why?
|
| Receptors, Peptide | 3 | 2003 | 18 | 0.260 |
Why?
|
| Thromboplastin | 2 | 2023 | 71 | 0.260 |
Why?
|
| Triazoles | 6 | 2001 | 131 | 0.250 |
Why?
|
| Colorado | 11 | 2019 | 4100 | 0.250 |
Why?
|
| Capillary Permeability | 2 | 2023 | 139 | 0.250 |
Why?
|
| CD40 Antigens | 1 | 2006 | 82 | 0.250 |
Why?
|
| Factor VII | 2 | 2013 | 26 | 0.250 |
Why?
|
| Up-Regulation | 6 | 2009 | 808 | 0.250 |
Why?
|
| Enzyme Inhibitors | 7 | 2009 | 750 | 0.250 |
Why?
|
| Lymph Nodes | 3 | 2014 | 419 | 0.250 |
Why?
|
| Flow Cytometry | 6 | 2015 | 1083 | 0.250 |
Why?
|
| Reactive Oxygen Species | 3 | 2012 | 531 | 0.250 |
Why?
|
| Random Allocation | 5 | 2023 | 335 | 0.240 |
Why?
|
| Peroxidase | 2 | 2003 | 163 | 0.240 |
Why?
|
| Hemostatics | 2 | 2023 | 47 | 0.240 |
Why?
|
| Analysis of Variance | 6 | 2013 | 1226 | 0.240 |
Why?
|
| Postoperative Complications | 3 | 2004 | 2128 | 0.240 |
Why?
|
| Protein Subunits | 1 | 2005 | 201 | 0.240 |
Why?
|
| Receptors, Immunologic | 3 | 2003 | 201 | 0.240 |
Why?
|
| Pulmonary Circulation | 1 | 2006 | 407 | 0.230 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 1342 | 0.230 |
Why?
|
| Prostatectomy | 1 | 2004 | 98 | 0.230 |
Why?
|
| Arginine | 2 | 2022 | 238 | 0.230 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2004 | 14 | 0.230 |
Why?
|
| Fluorescence Resonance Energy Transfer | 3 | 2010 | 170 | 0.220 |
Why?
|
| Lactic Acid | 4 | 2018 | 275 | 0.220 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 1796 | 0.220 |
Why?
|
| Models, Animal | 3 | 2017 | 344 | 0.220 |
Why?
|
| Transcription Factors | 2 | 2003 | 1528 | 0.220 |
Why?
|
| Hypoxia | 2 | 2022 | 958 | 0.220 |
Why?
|
| Imidazoles | 5 | 2003 | 208 | 0.220 |
Why?
|
| Compartment Syndromes | 1 | 2003 | 30 | 0.220 |
Why?
|
| Blood Physiological Phenomena | 1 | 2003 | 14 | 0.220 |
Why?
|
| Hypocalcemia | 1 | 2023 | 31 | 0.220 |
Why?
|
| Rodentia | 1 | 2023 | 44 | 0.210 |
Why?
|
| Hypotension | 1 | 2004 | 116 | 0.210 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2003 | 61 | 0.210 |
Why?
|
| Acidosis | 2 | 2016 | 88 | 0.210 |
Why?
|
| Serpins | 1 | 2022 | 25 | 0.210 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2003 | 95 | 0.200 |
Why?
|
| von Willebrand Factor | 1 | 2022 | 56 | 0.200 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2022 | 73 | 0.200 |
Why?
|
| Hemophilia A | 2 | 2013 | 69 | 0.200 |
Why?
|
| Complement C4 | 1 | 2022 | 25 | 0.200 |
Why?
|
| Hospital Mortality | 3 | 2017 | 776 | 0.200 |
Why?
|
| Caspases | 1 | 2003 | 245 | 0.200 |
Why?
|
| Treatment Outcome | 10 | 2017 | 9088 | 0.200 |
Why?
|
| Retrospective Studies | 13 | 2023 | 12555 | 0.200 |
Why?
|
| Alcoholic Intoxication | 2 | 2020 | 62 | 0.200 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2018 | 470 | 0.200 |
Why?
|
| Mice | 12 | 2022 | 14871 | 0.200 |
Why?
|
| Endothelium | 2 | 2016 | 111 | 0.190 |
Why?
|
| Acute Disease | 5 | 2011 | 911 | 0.190 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2022 | 124 | 0.190 |
Why?
|
| Sex Factors | 6 | 2023 | 1715 | 0.190 |
Why?
|
| Asparaginase | 2 | 1998 | 31 | 0.190 |
Why?
|
| Plasmapheresis | 1 | 2001 | 22 | 0.180 |
Why?
|
| Platelet Activation | 3 | 2022 | 68 | 0.180 |
Why?
|
| Pyridoxal Phosphate | 1 | 2001 | 20 | 0.180 |
Why?
|
| Complement Activation | 2 | 2022 | 340 | 0.180 |
Why?
|
| Young Adult | 10 | 2020 | 10471 | 0.180 |
Why?
|
| Blotting, Western | 3 | 2017 | 1147 | 0.180 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 168 | 0.180 |
Why?
|
| Tissue Extracts | 1 | 2000 | 20 | 0.180 |
Why?
|
| Blood Volume | 2 | 2015 | 59 | 0.180 |
Why?
|
| Interleukin-6 | 3 | 2003 | 676 | 0.180 |
Why?
|
| Femoral Fractures | 2 | 2017 | 66 | 0.180 |
Why?
|
| Pregnancy | 4 | 2022 | 5520 | 0.180 |
Why?
|
| Pancreatitis | 2 | 1998 | 107 | 0.170 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2023 | 223 | 0.170 |
Why?
|
| NF-kappa B | 4 | 2017 | 641 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 181 | 0.170 |
Why?
|
| Chemokines | 1 | 2021 | 216 | 0.170 |
Why?
|
| Blood Viscosity | 2 | 2019 | 16 | 0.170 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 1430 | 0.170 |
Why?
|
| Cyclic GMP | 2 | 1997 | 80 | 0.170 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1998 | 172 | 0.170 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 1693 | 0.170 |
Why?
|
| Phospholipids | 1 | 2001 | 197 | 0.160 |
Why?
|
| Myosins | 1 | 2019 | 126 | 0.160 |
Why?
|
| Intracranial Hypertension | 1 | 2019 | 37 | 0.160 |
Why?
|
| Blood Pressure | 4 | 2014 | 1538 | 0.160 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2018 | 511 | 0.160 |
Why?
|
| Factor XIII | 2 | 2023 | 7 | 0.160 |
Why?
|
| Complement Pathway, Alternative | 1 | 2020 | 114 | 0.160 |
Why?
|
| Testosterone | 1 | 2022 | 343 | 0.160 |
Why?
|
| beta-Arrestin 1 | 2 | 2010 | 6 | 0.160 |
Why?
|
| beta-Arrestins | 2 | 2010 | 12 | 0.160 |
Why?
|
| Blood Buffy Coat | 1 | 2018 | 5 | 0.160 |
Why?
|
| Monomeric Clathrin Assembly Proteins | 1 | 1998 | 5 | 0.160 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1998 | 13 | 0.160 |
Why?
|
| Methods | 1 | 2018 | 58 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1998 | 18 | 0.160 |
Why?
|
| Pyridines | 4 | 2003 | 425 | 0.160 |
Why?
|
| Phosphatidic Acids | 1 | 1998 | 9 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1998 | 58 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2014 | 1842 | 0.150 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 1 | 2018 | 5 | 0.150 |
Why?
|
| Fluid Therapy | 2 | 2016 | 123 | 0.150 |
Why?
|
| Microscopy, Fluorescence | 2 | 2010 | 396 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2012 | 498 | 0.150 |
Why?
|
| Culture Media, Conditioned | 2 | 2017 | 105 | 0.150 |
Why?
|
| Hemagglutinins | 1 | 2018 | 9 | 0.150 |
Why?
|
| Ambulances | 1 | 2018 | 50 | 0.150 |
Why?
|
| Blood Bactericidal Activity | 1 | 1998 | 36 | 0.150 |
Why?
|
| Solutions | 1 | 2018 | 146 | 0.150 |
Why?
|
| Endopeptidases | 1 | 1998 | 71 | 0.150 |
Why?
|
| Alprostadil | 1 | 1998 | 32 | 0.150 |
Why?
|
| Cycloheximide | 1 | 2018 | 54 | 0.150 |
Why?
|
| Angiostatins | 1 | 2017 | 3 | 0.150 |
Why?
|
| Chelating Agents | 4 | 2002 | 65 | 0.150 |
Why?
|
| Glycolysis | 2 | 2018 | 227 | 0.150 |
Why?
|
| Octreotide | 1 | 1998 | 26 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 140 | 0.150 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2018 | 42 | 0.150 |
Why?
|
| Histocompatibility Testing | 1 | 2018 | 116 | 0.150 |
Why?
|
| Signal Transduction | 8 | 2017 | 4515 | 0.150 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 2320 | 0.150 |
Why?
|
| Molsidomine | 1 | 1997 | 5 | 0.150 |
Why?
|
| Incidence | 4 | 2019 | 2313 | 0.140 |
Why?
|
| Dynamin II | 2 | 2008 | 6 | 0.140 |
Why?
|
| Receptors, Formyl Peptide | 3 | 2003 | 9 | 0.140 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 921 | 0.140 |
Why?
|
| Cohort Studies | 7 | 2023 | 4895 | 0.140 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 1998 | 54 | 0.140 |
Why?
|
| Myocardium | 2 | 2019 | 913 | 0.140 |
Why?
|
| Calcium Signaling | 3 | 2023 | 217 | 0.140 |
Why?
|
| Cell Movement | 3 | 2017 | 869 | 0.140 |
Why?
|
| Isoproterenol | 1 | 1997 | 106 | 0.140 |
Why?
|
| Freeze Drying | 1 | 2017 | 75 | 0.140 |
Why?
|
| Alternative Splicing | 1 | 1998 | 187 | 0.140 |
Why?
|
| Nitric Oxide | 2 | 2022 | 823 | 0.140 |
Why?
|
| Consensus | 1 | 2019 | 537 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2020 | 337 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 1998 | 179 | 0.140 |
Why?
|
| Bone Marrow | 1 | 1998 | 243 | 0.140 |
Why?
|
| Cell Death | 1 | 1998 | 323 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1997 | 127 | 0.130 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 126 | 0.130 |
Why?
|
| Critical Care | 4 | 2015 | 476 | 0.130 |
Why?
|
| Risk Assessment | 8 | 2021 | 2968 | 0.130 |
Why?
|
| Group II Phospholipases A2 | 3 | 2002 | 19 | 0.130 |
Why?
|
| Calcium-Binding Proteins | 1 | 1997 | 206 | 0.130 |
Why?
|
| Perioperative Care | 1 | 2017 | 127 | 0.130 |
Why?
|
| Cell Communication | 2 | 2013 | 280 | 0.130 |
Why?
|
| Hemodynamics | 2 | 2015 | 1012 | 0.130 |
Why?
|
| Phosphates | 2 | 2014 | 159 | 0.130 |
Why?
|
| Brain Death | 1 | 2016 | 31 | 0.130 |
Why?
|
| Platelet Count | 2 | 2013 | 81 | 0.130 |
Why?
|
| Protein Biosynthesis | 1 | 2018 | 386 | 0.130 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2009 | 130 | 0.130 |
Why?
|
| Metabolic Flux Analysis | 1 | 2015 | 7 | 0.130 |
Why?
|
| Patient Selection | 2 | 2018 | 641 | 0.130 |
Why?
|
| Goals | 1 | 2017 | 147 | 0.130 |
Why?
|
| Oxidative Stress | 4 | 2014 | 1076 | 0.120 |
Why?
|
| Taurocholic Acid | 1 | 2015 | 34 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 560 | 0.120 |
Why?
|
| Purines | 1 | 2016 | 159 | 0.120 |
Why?
|
| Ligands | 2 | 2008 | 562 | 0.120 |
Why?
|
| Isotope Labeling | 1 | 2015 | 69 | 0.120 |
Why?
|
| Citrates | 1 | 2014 | 43 | 0.120 |
Why?
|
| Intensive Care Units | 2 | 2010 | 617 | 0.120 |
Why?
|
| Elasticity | 1 | 2015 | 189 | 0.120 |
Why?
|
| Phospholipases A2 | 3 | 2000 | 76 | 0.120 |
Why?
|
| Critical Illness | 2 | 2017 | 646 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 1 | 1998 | 529 | 0.120 |
Why?
|
| Epithelial Cells | 2 | 2017 | 951 | 0.120 |
Why?
|
| Child, Preschool | 8 | 2016 | 9118 | 0.120 |
Why?
|
| International Normalized Ratio | 3 | 2019 | 45 | 0.120 |
Why?
|
| Abdomen, Acute | 1 | 1994 | 18 | 0.120 |
Why?
|
| Macrophages | 2 | 2012 | 1263 | 0.120 |
Why?
|
| Immunoglobulin M | 1 | 1995 | 246 | 0.120 |
Why?
|
| Carbon | 1 | 2015 | 156 | 0.120 |
Why?
|
| 2,3-Diphosphoglycerate | 1 | 2014 | 29 | 0.120 |
Why?
|
| Heinz Bodies | 1 | 2014 | 1 | 0.110 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2014 | 12 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 290 | 0.110 |
Why?
|
| Child | 11 | 2019 | 18420 | 0.110 |
Why?
|
| Energy Metabolism | 2 | 2017 | 731 | 0.110 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1993 | 2 | 0.110 |
Why?
|
| Pertussis Toxin | 2 | 2003 | 26 | 0.110 |
Why?
|
| Emergency Medical Services | 2 | 2018 | 590 | 0.110 |
Why?
|
| Ethanol | 1 | 1998 | 538 | 0.110 |
Why?
|
| ROC Curve | 3 | 2021 | 442 | 0.110 |
Why?
|
| Hemosiderosis | 1 | 1993 | 2 | 0.110 |
Why?
|
| Deferoxamine | 1 | 1993 | 18 | 0.110 |
Why?
|
| Codon | 1 | 2014 | 86 | 0.110 |
Why?
|
| Protein Stability | 1 | 2014 | 157 | 0.110 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1993 | 8 | 0.110 |
Why?
|
| Coagulants | 1 | 2013 | 12 | 0.110 |
Why?
|
| Linear Models | 1 | 2015 | 768 | 0.110 |
Why?
|
| Adenine | 1 | 2014 | 219 | 0.110 |
Why?
|
| Heterozygote | 1 | 2014 | 251 | 0.110 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 262 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2014 | 217 | 0.100 |
Why?
|
| Siblings | 1 | 2014 | 221 | 0.100 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2012 | 23 | 0.100 |
Why?
|
| Isoflurane | 1 | 2012 | 8 | 0.100 |
Why?
|
| Logistic Models | 4 | 2020 | 1841 | 0.100 |
Why?
|
| Anesthetics, Inhalation | 1 | 2012 | 14 | 0.100 |
Why?
|
| Friend murine leukemia virus | 1 | 1993 | 30 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1993 | 90 | 0.100 |
Why?
|
| Exsanguination | 1 | 2012 | 16 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 370 | 0.100 |
Why?
|
| CD11 Antigens | 3 | 2003 | 30 | 0.100 |
Why?
|
| Blood Platelet Disorders | 1 | 2012 | 10 | 0.100 |
Why?
|
| Paecilomyces | 1 | 1992 | 2 | 0.100 |
Why?
|
| Abdominal Muscles | 1 | 1992 | 5 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 489 | 0.100 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2012 | 82 | 0.100 |
Why?
|
| Neoplasm Metastasis | 2 | 2013 | 523 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 1999 | 1314 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1993 | 217 | 0.100 |
Why?
|
| Cross-Linking Reagents | 2 | 2006 | 181 | 0.100 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 430 | 0.100 |
Why?
|
| Antigens, CD | 2 | 2008 | 442 | 0.100 |
Why?
|
| Encephalitis | 1 | 1993 | 127 | 0.100 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 1992 | 60 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 1995 | 770 | 0.100 |
Why?
|
| beta 2-Microglobulin | 1 | 2011 | 45 | 0.100 |
Why?
|
| Mycoses | 1 | 1992 | 67 | 0.090 |
Why?
|
| Immunocompromised Host | 2 | 2008 | 195 | 0.090 |
Why?
|
| Extravascular Lung Water | 1 | 2011 | 8 | 0.090 |
Why?
|
| Abscess | 1 | 1992 | 72 | 0.090 |
Why?
|
| I-kappa B Proteins | 2 | 2003 | 79 | 0.090 |
Why?
|
| Histones | 3 | 2022 | 535 | 0.090 |
Why?
|
| Splenectomy | 1 | 2011 | 52 | 0.090 |
Why?
|
| Vitamin K Deficiency | 1 | 1991 | 10 | 0.090 |
Why?
|
| G-Protein-Coupled Receptor Kinases | 1 | 2010 | 2 | 0.090 |
Why?
|
| Protein Binding | 1 | 2016 | 1890 | 0.090 |
Why?
|
| GTP-Binding Protein gamma Subunits | 1 | 2010 | 7 | 0.090 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1991 | 11 | 0.090 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2010 | 12 | 0.090 |
Why?
|
| Drug Design | 1 | 2012 | 148 | 0.090 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2010 | 13 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2016 | 520 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 785 | 0.090 |
Why?
|
| Hypothermia | 1 | 2011 | 38 | 0.090 |
Why?
|
| Ion Transport | 1 | 2010 | 55 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2005 | 5047 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 1473 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2013 | 241 | 0.090 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2011 | 103 | 0.090 |
Why?
|
| Aorta | 2 | 2023 | 386 | 0.090 |
Why?
|
| Oxidation-Reduction | 3 | 2018 | 923 | 0.090 |
Why?
|
| Mice, Knockout | 1 | 2016 | 2570 | 0.090 |
Why?
|
| Anemia, Sickle Cell | 1 | 1993 | 215 | 0.090 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 198 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 2010 | 54 | 0.090 |
Why?
|
| Chemotaxis | 2 | 2017 | 130 | 0.090 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2009 | 49 | 0.080 |
Why?
|
| Capillary Leak Syndrome | 1 | 2009 | 13 | 0.080 |
Why?
|
| Glucose | 1 | 2014 | 897 | 0.080 |
Why?
|
| Membrane Microdomains | 1 | 2009 | 32 | 0.080 |
Why?
|
| Glasgow Coma Scale | 2 | 2023 | 153 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 102 | 0.080 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 275 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2012 | 2710 | 0.080 |
Why?
|
| Herpes Zoster | 1 | 1993 | 331 | 0.080 |
Why?
|
| Rimantadine | 1 | 2009 | 2 | 0.080 |
Why?
|
| Partial Thromboplastin Time | 2 | 2019 | 51 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2009 | 283 | 0.080 |
Why?
|
| Parity | 1 | 2009 | 98 | 0.080 |
Why?
|
| RNA Interference | 1 | 2011 | 433 | 0.080 |
Why?
|
| Tetrahydronaphthalenes | 2 | 2020 | 31 | 0.080 |
Why?
|
| HMGB1 Protein | 1 | 2009 | 48 | 0.080 |
Why?
|
| Antigens, CD1 | 1 | 2009 | 57 | 0.080 |
Why?
|
| Heme Oxygenase-1 | 1 | 2009 | 52 | 0.080 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1999 | 153 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2009 | 268 | 0.080 |
Why?
|
| Granulocytes | 2 | 2000 | 77 | 0.080 |
Why?
|
| Cross Infection | 1 | 2011 | 197 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 1313 | 0.080 |
Why?
|
| Kaolin | 2 | 2018 | 5 | 0.080 |
Why?
|
| Fluorescent Dyes | 2 | 2002 | 301 | 0.080 |
Why?
|
| Adaptive Immunity | 1 | 2009 | 155 | 0.080 |
Why?
|
| Blood Banks | 2 | 2015 | 40 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 6347 | 0.070 |
Why?
|
| Chondroblastoma | 1 | 1987 | 4 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1989 | 174 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2008 | 83 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 506 | 0.070 |
Why?
|
| Molecular Weight | 2 | 2003 | 331 | 0.070 |
Why?
|
| Antigens | 1 | 2009 | 318 | 0.070 |
Why?
|
| Bevacizumab | 1 | 2008 | 115 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2009 | 218 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 1998 | 1879 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 638 | 0.070 |
Why?
|
| Risk | 2 | 2001 | 812 | 0.070 |
Why?
|
| Vesicular Transport Proteins | 1 | 2008 | 83 | 0.070 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1987 | 67 | 0.070 |
Why?
|
| Calcium Channel Blockers | 2 | 1998 | 114 | 0.070 |
Why?
|
| Kidney | 1 | 2014 | 1188 | 0.070 |
Why?
|
| Obesity | 1 | 2019 | 2508 | 0.070 |
Why?
|
| Indoles | 2 | 2001 | 304 | 0.070 |
Why?
|
| Osteosarcoma | 1 | 1987 | 67 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 2540 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 668 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2008 | 1862 | 0.070 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2006 | 3 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 4411 | 0.070 |
Why?
|
| Probability | 2 | 2004 | 289 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 214 | 0.070 |
Why?
|
| Immune Tolerance | 1 | 2008 | 323 | 0.070 |
Why?
|
| Interleukin-10 | 2 | 2012 | 299 | 0.070 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2006 | 50 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 281 | 0.070 |
Why?
|
| Leukotrienes | 2 | 2018 | 35 | 0.070 |
Why?
|
| Subcellular Fractions | 1 | 2006 | 78 | 0.070 |
Why?
|
| Coculture Techniques | 1 | 2006 | 201 | 0.070 |
Why?
|
| Erythroblastosis, Fetal | 1 | 2005 | 4 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 339 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 1993 | 1701 | 0.060 |
Why?
|
| Transplantation Conditioning | 2 | 2016 | 151 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 448 | 0.060 |
Why?
|
| Chemokine CCL5 | 2 | 2017 | 45 | 0.060 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 2018 | 124 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 1987 | 194 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2006 | 126 | 0.060 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2005 | 21 | 0.060 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 100 | 0.060 |
Why?
|
| Potassium Compounds | 1 | 2005 | 8 | 0.060 |
Why?
|
| Pulmonary Artery | 2 | 2003 | 1016 | 0.060 |
Why?
|
| Intraoperative Care | 1 | 2004 | 34 | 0.060 |
Why?
|
| Cytochromes c | 1 | 2004 | 63 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 93 | 0.060 |
Why?
|
| Infant | 3 | 2016 | 7964 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2009 | 720 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2016 | 455 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2017 | 1125 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 663 | 0.060 |
Why?
|
| Factor VIIa | 1 | 2004 | 36 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2286 | 0.060 |
Why?
|
| TRPV Cation Channels | 1 | 2023 | 31 | 0.050 |
Why?
|
| Mutation | 1 | 2014 | 3346 | 0.050 |
Why?
|
| Cell Survival | 1 | 2006 | 1021 | 0.050 |
Why?
|
| Blood Group Incompatibility | 2 | 2018 | 14 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2187 | 0.050 |
Why?
|
| Survival Rate | 2 | 2018 | 1644 | 0.050 |
Why?
|
| Lactoferrin | 1 | 2003 | 28 | 0.050 |
Why?
|
| Interleukin-11 | 1 | 2003 | 9 | 0.050 |
Why?
|
| Factor V | 1 | 2023 | 22 | 0.050 |
Why?
|
| Acute-Phase Proteins | 2 | 2014 | 64 | 0.050 |
Why?
|
| Substrate Specificity | 2 | 1997 | 352 | 0.050 |
Why?
|
| Caspase Inhibitors | 1 | 2003 | 78 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2004 | 137 | 0.050 |
Why?
|
| Reperfusion | 1 | 2023 | 36 | 0.050 |
Why?
|
| Group IB Phospholipases A2 | 1 | 2002 | 2 | 0.050 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2002 | 2 | 0.050 |
Why?
|
| E-Selectin | 1 | 2003 | 53 | 0.050 |
Why?
|
| Arginase | 1 | 2022 | 27 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2004 | 117 | 0.050 |
Why?
|
| Perfusion | 1 | 2003 | 148 | 0.050 |
Why?
|
| United States | 4 | 2019 | 12186 | 0.050 |
Why?
|
| P-Selectin | 1 | 2022 | 25 | 0.050 |
Why?
|
| Serine | 1 | 2003 | 126 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2002 | 193 | 0.050 |
Why?
|
| Cell Size | 1 | 2002 | 80 | 0.050 |
Why?
|
| Apolipoprotein A-I | 1 | 2022 | 25 | 0.050 |
Why?
|
| CD36 Antigens | 1 | 2022 | 37 | 0.050 |
Why?
|
| Citrulline | 1 | 2022 | 40 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2003 | 235 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 309 | 0.050 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2022 | 89 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2003 | 168 | 0.050 |
Why?
|
| Transcription Factor RelA | 2 | 2014 | 82 | 0.050 |
Why?
|
| Cell Line | 4 | 2014 | 2637 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 932 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2003 | 236 | 0.050 |
Why?
|
| Mitochondrial Proteins | 2 | 2015 | 219 | 0.050 |
Why?
|
| Cell Separation | 1 | 2002 | 291 | 0.050 |
Why?
|
| Brachytherapy | 1 | 2002 | 103 | 0.050 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 347 | 0.050 |
Why?
|
| Tissue Preservation | 1 | 2001 | 12 | 0.050 |
Why?
|
| Wilms Tumor | 1 | 2002 | 68 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2004 | 513 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 2017 | 554 | 0.050 |
Why?
|
| Maleimides | 1 | 2001 | 24 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2023 | 221 | 0.050 |
Why?
|
| Neoplasms | 1 | 1994 | 2097 | 0.040 |
Why?
|
| Polymyxin B | 1 | 2000 | 21 | 0.040 |
Why?
|
| Research Design | 2 | 2017 | 928 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2014 | 412 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2012 | 849 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2023 | 381 | 0.040 |
Why?
|
| Elapid Venoms | 1 | 2020 | 15 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2001 | 316 | 0.040 |
Why?
|
| Kinetics | 2 | 1997 | 1551 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 395 | 0.040 |
Why?
|
| Cyclic AMP | 2 | 1993 | 227 | 0.040 |
Why?
|
| Blood | 2 | 2005 | 96 | 0.040 |
Why?
|
| Neutrophil Infiltration | 2 | 2012 | 96 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2004 | 664 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 398 | 0.040 |
Why?
|
| Hematocrit | 1 | 2000 | 87 | 0.040 |
Why?
|
| Receptors, Fibrinogen | 1 | 2019 | 1 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2020 | 70 | 0.040 |
Why?
|
| Coagulation Protein Disorders | 1 | 2019 | 1 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2001 | 155 | 0.040 |
Why?
|
| Ischemia | 1 | 2023 | 362 | 0.040 |
Why?
|
| Complement Inactivating Agents | 1 | 2020 | 41 | 0.040 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 60 | 0.040 |
Why?
|
| Blood Coagulation Factors | 1 | 2019 | 44 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 87 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2000 | 161 | 0.040 |
Why?
|
| Premenopause | 1 | 2019 | 106 | 0.040 |
Why?
|
| Rhodamines | 1 | 1999 | 17 | 0.040 |
Why?
|
| Water | 1 | 2022 | 396 | 0.040 |
Why?
|
| Elapidae | 1 | 1998 | 5 | 0.040 |
Why?
|
| Sheep | 2 | 2012 | 764 | 0.040 |
Why?
|
| Torso | 1 | 2019 | 30 | 0.040 |
Why?
|
| Nitrates | 1 | 1999 | 72 | 0.040 |
Why?
|
| Nitrites | 1 | 1999 | 75 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1629 | 0.040 |
Why?
|
| Disease Progression | 2 | 2017 | 2380 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2019 | 160 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1998 | 71 | 0.040 |
Why?
|
| Gene Expression | 1 | 2003 | 1421 | 0.040 |
Why?
|
| RNA | 1 | 2004 | 809 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 1999 | 159 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 1998 | 50 | 0.040 |
Why?
|
| Mibefradil | 1 | 1998 | 6 | 0.040 |
Why?
|
| Peptides, Cyclic | 1 | 2020 | 253 | 0.040 |
Why?
|
| Lymphokines | 1 | 1998 | 111 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 1998 | 45 | 0.040 |
Why?
|
| Citric Acid | 1 | 2018 | 30 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1998 | 75 | 0.040 |
Why?
|
| Extremities | 1 | 2019 | 113 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 327 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 322 | 0.040 |
Why?
|
| CHO Cells | 1 | 1998 | 138 | 0.040 |
Why?
|
| Capillaries | 1 | 1998 | 91 | 0.040 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2017 | 14 | 0.040 |
Why?
|
| Leukotriene E4 | 1 | 1998 | 27 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2002 | 398 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 1998 | 256 | 0.040 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2017 | 16 | 0.040 |
Why?
|
| Antibody Affinity | 1 | 2018 | 52 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 157 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2019 | 187 | 0.040 |
Why?
|
| Cricetinae | 1 | 1998 | 253 | 0.040 |
Why?
|
| Cytochrome c Group | 1 | 1997 | 36 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 740 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 274 | 0.040 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1999 | 254 | 0.040 |
Why?
|
| Crush Injuries | 1 | 2017 | 10 | 0.040 |
Why?
|
| Dibutyryl Cyclic GMP | 1 | 1997 | 2 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2018 | 176 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2018 | 139 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 410 | 0.040 |
Why?
|
| Postmenopause | 1 | 2019 | 303 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 2017 | 64 | 0.040 |
Why?
|
| Species Specificity | 1 | 1999 | 542 | 0.040 |
Why?
|
| Exons | 1 | 1998 | 302 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 1998 | 97 | 0.040 |
Why?
|
| Swine, Miniature | 1 | 2017 | 71 | 0.040 |
Why?
|
| Colforsin | 1 | 1997 | 48 | 0.040 |
Why?
|
| Lactates | 1 | 2017 | 79 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2015 | 1211 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2004 | 1346 | 0.040 |
Why?
|
| Anaerobiosis | 1 | 2017 | 49 | 0.030 |
Why?
|
| Primates | 1 | 2018 | 111 | 0.030 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2017 | 80 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 1998 | 138 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 858 | 0.030 |
Why?
|
| Calcium Channels | 1 | 1997 | 145 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 144 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1998 | 2785 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2002 | 1019 | 0.030 |
Why?
|
| Glutamine | 1 | 2016 | 91 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2010 | 337 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2016 | 37 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2018 | 314 | 0.030 |
Why?
|
| Military Personnel | 2 | 2014 | 524 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 70 | 0.030 |
Why?
|
| Transfection | 1 | 1998 | 866 | 0.030 |
Why?
|
| Oxygen | 1 | 2000 | 854 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2002 | 1121 | 0.030 |
Why?
|
| Spleen | 1 | 2017 | 487 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 696 | 0.030 |
Why?
|
| Epitopes | 1 | 2018 | 435 | 0.030 |
Why?
|
| Systems Theory | 1 | 2015 | 5 | 0.030 |
Why?
|
| Alarmins | 1 | 2015 | 25 | 0.030 |
Why?
|
| Length of Stay | 2 | 2011 | 962 | 0.030 |
Why?
|
| Bacterial Translocation | 1 | 2015 | 36 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2017 | 220 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1320 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 289 | 0.030 |
Why?
|
| Gelsolin | 1 | 2014 | 9 | 0.030 |
Why?
|
| Serine Proteases | 1 | 2014 | 14 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1997 | 594 | 0.030 |
Why?
|
| Kallikreins | 1 | 2014 | 30 | 0.030 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 1994 | 21 | 0.030 |
Why?
|
| Thoracotomy | 1 | 2015 | 75 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2018 | 292 | 0.030 |
Why?
|
| Warfare | 1 | 2015 | 75 | 0.030 |
Why?
|
| Base Sequence | 1 | 1998 | 2114 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1999 | 966 | 0.030 |
Why?
|
| Intestines | 1 | 2017 | 326 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2016 | 350 | 0.030 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 1994 | 19 | 0.030 |
Why?
|
| Reference Values | 1 | 1995 | 743 | 0.030 |
Why?
|
| Cold Temperature | 1 | 2014 | 126 | 0.030 |
Why?
|
| Acetylation | 1 | 1994 | 211 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 104 | 0.030 |
Why?
|
| Fetal Blood | 1 | 1995 | 270 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2017 | 374 | 0.030 |
Why?
|
| Laparotomy | 1 | 1994 | 103 | 0.030 |
Why?
|
| Brain | 2 | 2016 | 2371 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2014 | 127 | 0.030 |
Why?
|
| Military Medicine | 1 | 2015 | 93 | 0.030 |
Why?
|
| Iron Chelating Agents | 1 | 1993 | 16 | 0.030 |
Why?
|
| Emergencies | 1 | 1994 | 146 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 162 | 0.030 |
Why?
|
| Aphidicolin | 1 | 1993 | 6 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2013 | 35 | 0.030 |
Why?
|
| Registries | 2 | 2015 | 1768 | 0.030 |
Why?
|
| Appendicitis | 1 | 1994 | 114 | 0.030 |
Why?
|
| Factor VIII | 1 | 2013 | 53 | 0.030 |
Why?
|
| Physical Examination | 1 | 1994 | 222 | 0.030 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1993 | 43 | 0.030 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2012 | 6 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2013 | 56 | 0.030 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2012 | 20 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2013 | 293 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2013 | 161 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 486 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2012 | 78 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2019 | 1959 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2012 | 55 | 0.020 |
Why?
|
| Amphotericin B | 1 | 1992 | 29 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 182 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 588 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2012 | 4694 | 0.020 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2012 | 62 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2012 | 97 | 0.020 |
Why?
|
| Radiography | 1 | 1994 | 812 | 0.020 |
Why?
|
| Iron | 1 | 1993 | 233 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2012 | 105 | 0.020 |
Why?
|
| Photochemistry | 1 | 2012 | 125 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 397 | 0.020 |
Why?
|
| Whole Blood Coagulation Time | 1 | 1991 | 3 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2012 | 151 | 0.020 |
Why?
|
| Emergency Medicine | 1 | 2014 | 221 | 0.020 |
Why?
|
| Macrophage Activation | 1 | 2012 | 164 | 0.020 |
Why?
|
| Feces | 1 | 1993 | 373 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2011 | 133 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2012 | 641 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1998 | 979 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2010 | 49 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 318 | 0.020 |
Why?
|
| Zinc | 1 | 1993 | 260 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 1737 | 0.020 |
Why?
|
| Diarrhea | 1 | 1991 | 171 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2010 | 59 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 493 | 0.020 |
Why?
|
| Herpesvirus 3, Human | 1 | 1993 | 378 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 1989 | 16 | 0.020 |
Why?
|
| Cell Transplantation | 1 | 2009 | 36 | 0.020 |
Why?
|
| Protoporphyrins | 1 | 2009 | 17 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2011 | 330 | 0.020 |
Why?
|
| Recurrence | 1 | 1992 | 935 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2009 | 84 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1993 | 1660 | 0.020 |
Why?
|
| Leukosialin | 1 | 2008 | 15 | 0.020 |
Why?
|
| Paracrine Communication | 1 | 2009 | 56 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 2009 | 116 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 430 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2008 | 57 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2009 | 110 | 0.020 |
Why?
|
| Tubulin | 1 | 1989 | 123 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 953 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2008 | 22 | 0.020 |
Why?
|
| Shock | 1 | 2009 | 84 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2010 | 430 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 1448 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 1214 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2011 | 695 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 599 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 442 | 0.020 |
Why?
|
| Cattle | 1 | 1989 | 920 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 2251 | 0.020 |
Why?
|
| Body Weight | 1 | 2010 | 869 | 0.020 |
Why?
|
| Binding Sites | 1 | 1989 | 1168 | 0.020 |
Why?
|
| Extracorporeal Circulation | 1 | 2005 | 14 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2009 | 1037 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 1989 | 666 | 0.020 |
Why?
|
| Syndrome | 1 | 2005 | 333 | 0.010 |
Why?
|
| Global Health | 1 | 2005 | 287 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2005 | 778 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 2894 | 0.010 |
Why?
|
| Kidney Pelvis | 1 | 2002 | 20 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 342 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2001 | 58 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2001 | 284 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 1999 | 146 | 0.010 |
Why?
|
| Megakaryocytes | 1 | 1998 | 30 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1998 | 61 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 1395 | 0.010 |
Why?
|
| Epinephrine | 1 | 1998 | 164 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1996 | 24 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1996 | 56 | 0.010 |
Why?
|
| Collagen | 1 | 1998 | 415 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 1982 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 3053 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1998 | 2553 | 0.010 |
Why?
|